{
    "nctId": "NCT04105582",
    "briefTitle": "Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells",
    "officialTitle": "Phase I Clinical Study of Immunotherapy With Personalized Synthetic Vaccines in Patients With Triple Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Adverse effects and Safety",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Be a patient who is prescribed as a treatment for her cancer initiating neo-adjuvant chemotherapy with Doxorubicin / cyclophosphamide (A / C) administered prior to cycles with Taxanes and followed by surgery to remove the tumor.\n* Be between 18 and 75 years old.\n* That the patient agrees to participate in the Clinical Study prior to the start of chemotherapy.\n* Have free venous access.\n* Signature of informed consent.\n\nExclusion Criteria:\n\n* Heart disease.\n* Diabetes\n* Renal impairment\n* Coagulation disorders\n* Have been hospitalized in the last month\n* Have another active tumor with the exception of skin tumors of the squamous-cell or basal-cell carcinoma.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}